Ramaswamy Govindan
Washington University in St. Louis
551 Papers
2.9K Citations
Ramaswamy Govindan is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 85, co-authored 499 publications. Previous affiliations of Ramaswamy Govindan include University of North Carolina at Chapel Hill & Medical University of South Carolina.
Chat about Author
Papers
Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update.
Hak Choy,Lee S. Schwartzberg,Shaker R. Dakhil,Edward B. Garon,Janak K. Choksi,Ramaswamy Govindan,Guangbin Peng,Andrew Koustenis,J. Treat,Coleman K. Obasaju +9 more
TL;DR: There is no consensus chemotherapy regimen with concurrent radiation therapy (CRT) for inoperable stage IIIA/B non-small cell lung cancer (NSCLC).
7
[A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer].
TL;DR: Although reversible EGFR tyrosine kinase inhibitor erlotinib improves survival in patients with relapsed and recurrent NSCLC, significant limitations exist, including the restriction of clinical efficacy to a small patient subset, poor survival rates, and the development of resistance as discussed by the authors.
7
Management of patients with advanced non-small cell lung cancer: role of gefitinib.
TL;DR: Gefitinib significantly improved progression-free survival compared to chemotherapy in patients with activating mutations in the epidermal growth factor receptor tyrosine kinase mutations and the role in the treatment of advanced NSCLC is discussed.
Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study.
Fadlo R. Khuri,Taofeek K. Owonikoko,Janakiraman Subramanian,Gabriel Sica,Madhusmita Behera,Nabil F. Saba,Zhengjia Chen,Mourad Tighiouart,Dong M. Shin,Shi-Yong Sun,R. Fu,Anthony A. Gal,Ramaswamy Govindan,S.S. Ramalingam +13 more
TL;DR: The combination of everolimus and docetaxel was tolerated well, but there was no clear signal of enhanced efficacy in an unselected population of NSCLC patients.
7
A phase I study of docetaxel and bexarotene
TL;DR: Combination of docetaxel and bexarotene is well tolerated and accrual to the final cohort is continuing and Updated results will be presented at the annual meeting.
7